BioAmber Inc. has announced that Jean-Francois Huc has resigned as President and CEO and Fabrice Orecchioni, the company’s COO, has been named President, effective immediately.
In his role as COO over the past four years, Fabrice has overseen the construction, start-up and operation of the manufacturing plant in Sarnia and the management of the Mitsui JV. Fabrice has also been extensively involved in the negotiations with CJ CheilJedang for the proposed China JV.
Mr. Huc, who stepped down for personal reasons, will remain a member of the board of directors and will also assume an advisory role with the management team to help ensure a smooth transition.
Source: BioAmber
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
